-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, in the European Journal of Cancer, the post-hoc analysis results of the phase III clinical study LATITUDE were published, mainly evaluating the effect of abiraterone acetate combined with prednisone (AA+P) on metastatic castration-sensitive prostate cancer (mCSPC) with visceral metastasis.
Recently, in the European Journal of Cancer, the post-hoc analysis results of the phase III clinical study LATITUDE were published, mainly evaluating the effect of abiraterone acetate combined with prednisone (AA+P) on metastatic castration-sensitive prostate cancer (mCSPC) with visceral metastasis.
Newly diagnosed mCSPC patients were randomized (1:1) to AA+P and androgen deprivation therapy (ADT) or placebo+ADT
Newly diagnosed mCSPC patients were randomized (1:1) to AA+P and androgen deprivation therapy (ADT) or placebo+ADT
1199 patients were randomized to AA+P+ADT (n=597) or placebo+ADT (n=602)
With a median follow-up of 51.
Overall Population Treatment Prognosis Differences
In subgroup analysis, among patients with lung metastases, the AA+P+ADT group improved the median OS of the patients compared with the placebo+ADT group by 57.
In subgroup analysis, among patients with lung metastases, the AA+P+ADT group improved the median OS of the patients compared with the placebo+ADT group by 57.
OS subgroup analysis
Subgroup analysis
Among patients with lung metastases, the AA+P+ADT group improved the median rPFS of the patients compared with the placebo+ADT group by 33 and 21.
Among patients with lung metastases, the AA+P+ADT group improved the median rPFS of the patients compared with the placebo+ADT group by 33 and 21.
rPFS subgroup analysis
In the general population, the incidence of AEs in the two groups was 98.
In the general population, the incidence of AEs in the two groups was 98.
In conclusion, the study showed that abiraterone acetate combined with prednisone (AA+P) treatment could improve rPFS and OS in patients with mCSPC and visceral metastases, especially in patients with pulmonary metastases
.
Studies have shown that abiraterone acetate combined with prednisone (AA+P) treatment can improve rPFS and OS in patients with mCSPC and visceral metastases, especially in patients with lung metastases
.
Studies have shown that abiraterone acetate combined with prednisone (AA+P) treatment can improve rPFS and OS in patients with mCSPC and visceral metastases, especially in patients with lung metastases
.
Original source:
Original source:Baciarello G, Özgüroğlu M, Mundle S, Leitz G, Richarz U, Hu P, Feyerabend S, Matsubara N, Chi KN, Fizazi K.
Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study.
Eur J Cancer.
2021 Dec 22;162:56-64.
doi: 10.
1016/j.
ejca.
2021.
11.
026.
Epub ahead of print.
PMID: 34953443 .
Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study.
Eur J Cancer.
2021 Dec 22;162:56-64.
doi: 10.
1016/j.
ejca.
2021.
11.
026.
Epub ahead of print.
PMID: 34953443 .
leave a message here
